The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).
 
Fabrice Andre
Stock and Other Ownership Interests - PEGASCY
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Peter Schmid
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech (I); Merck; Novartis; Pfizer; Puma Biotechnology; Roche; Roche (I)
Research Funding - Astellas Pharma; AstraZeneca; Genentech; Novartis; OncoGenex; Roche
 
Carey K. Anders
Honoraria - AstraZeneca; Eisai; Elucida Oncology; Genentech/Roche; Immunomedics; IPSEN; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca; Eisai; Elucida Oncology; Genentech/Roche; Immunomedics; Ipsen; Puma Biotechnology; Seagen
Research Funding - G1 Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Tesaro (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; Up to Date.com
Travel, Accommodations, Expenses - Eisai
 
Tinghui Yu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Sarice Boston
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Celina M. D'Cruz
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Pia Herbolsheimer
No Relationships to Disclose
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BluePrint Medicines; Bristol-Myers Squibb; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Synthon; Taiho Pharmaceutical
Research Funding - ADC Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical